Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

Idiopathic Pulmonary Fibrosis: Clinically Meaningful Primary Endpoints in Phase 3 Clinical Trials

Open access
Raghu, Ganesh, Collard, Harold R., Anstrom, Kevin J., Flaherty, Kevin R., Fleming, Thomas R., King, Talmadge E., Martinez, Fernando J., Brown, Kevin K. · 2012 · American Journal of Respiratory and Critical Care Medicine

Abstract

Definitive evidence of clinical efficacy in a Phase 3 trial is best shown by a beneficial impact on a clinically meaningful endpoint—that is, an endpoint that directly measures how a patient feels (symptoms), functions (the ability to perform activities in daily life), or survives. In idiopathic pulmonary fibrosis (IPF), we believe the endpoints that best meet these criteria are all-cause mortality and all-cause nonelective hospitalization. There are no validated measures of symptoms or broader constructs such as health status or funtional status in IPF. A surrogate endpoint is defined as an indirect measure that is intended to substitute for a clinically meaningful endpoint. Surrogate endpoints can be appropriate outcome measures if validated. However, validation requires substantial evidence that the effect of an intervention on a clinically meaningful endpoint is reliably predicted by the effect of an intervention on the surrogate endpoint. For patients with IPF, there are currently no validated surrogate endpoints.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/rccm.201201-0006pp

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 29 · Cited by 242

Metadata

Authors
Raghu, G., Collard, H. R., Anstrom, K. J., Flaherty, K. R., Fleming, T. R., King, T. E., Martinez, F. J., & Brown, K. K.
Affiliations
  • University of Washington (US)
  • University of California, San Francisco (US)
  • Duke University (US)
  • University of Michigan (US)
  • Department of Medicine, University of Michigan, Ann Arbor, Michigan; and
  • National Jewish Health (US)
Corresponding author
Raghu, Ganesh
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2012-05
Volume
185
Issue
10
Pages
1044-1048
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W1984774336
Cited by
242
References
29
Citations by year
2026: 5 · 2025: 4 · 2024: 9 · 2023: 13 · 2022: 10 · 2021: 13 · 2020: 14 · 2019: 16 · 2018: 16 · 2017: 11 · 2016: 23 · 2015: 32 · 2014: 22 · 2013: 37 · 2012: 16
FWCI
27.61
Type
journal article
Language
en
Open access
Locations
  • American Journal of Respiratory and Critical Care Medicine (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Pulmonary Fibrosis Foundation
  • National Heart, Lung, and Blood Institute (K24HL111316)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
Keywords
idiopathic pulmonary fibrosis, primary endpoint, surrogate endpoints, all-cause mortality, clinical trial outcome measures, endpoint validation, functional status
MeSH terms
Hospitalization, Humans, Severity of Illness Index, Biomarkers, Survival Analysis, Lung Transplantation, Treatment Outcome, Clinical Trials, Phase III as Topic, Respiratory System Agents, Endpoint Determination, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Idiopathic Pulmonary Fibrosis: Clinically Meaningful Primary Endpoints in Phase 3 Clinical Trials. https://app.cochat.ai/papers/10.1164/rccm.201201-0006pp
The paper
Raghu, G., Collard, H. R., Anstrom, K. J., Flaherty, K. R., Fleming, T. R., King, T. E., Martinez, F. J., & Brown, K. K. (2012). Idiopathic Pulmonary Fibrosis: Clinically Meaningful Primary Endpoints in Phase 3 Clinical Trials. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201201-0006pp

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.